Skip to main content

Table 2 Treatment arms

From: Efficacy and safety of a booster dose of influenza vaccination in solid organ transplant recipients, TRANSGRIPE 1-2: study protocol for a multicenter, randomized, controlled clinical trial

Treatment arm Description
Standard influenza vaccination (treatment arm A) Single intramuscular 0.5-ml dose of inactivated influenza vaccine (split virion) containing World Health Organization (WHO)–recommended strains in Northern Hemisphere and European Union (EU) decision for the 2012–2013 season (A/California/7/2009(H1N1)pdm09-like, A/Victoria/361/2011-like and B/Wisconsin/1/2010-like strains, derived from B/Hubei- Wujiagang/158/2009)
Booster double-dose influenza vaccination (treatment arm B) Single standard intramuscular 0.5-ml dose of inactivated influenza vaccine (split virion), followed by a second booster dose of the same vaccine 5 weeks later;vaccine strain used was in compliance with the WHO recommendations in Northern Hemisphere and EU decision for the 2012–2013 season (A/California/7/2009(H1N1)pdm09-, A/Victoria/361/2011- and B/Wisconsin/1/2010-like strains, derived from B/Hubei- Wujiagang/158/2009)